Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright

aTyr Pharma, Inc. (NASDAQ:ATYR) – Stock analysts at HC Wainwright boosted their Q3 2026 EPS estimates for shares of aTyr Pharma in a note issued to investors on Monday, August 10th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.10) per share for the quarter, up from their prior forecast of ($0.18). The consensus estimate for aTyr Pharma’s current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for aTyr Pharma’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.34) EPS and FY2028 earnings at ($0.38) EPS.

ATYR has been the subject of a number of other reports. Freedom Capital upgraded aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th. Wall Street Zen upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings cut shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $17.00.

aTyr Pharma Stock Performance

ATYR opened at $0.53 on Wednesday. aTyr Pharma has a 52-week low of $0.40 and a 52-week high of $6.50. The firm has a market capitalization of $52.38 million, a PE ratio of -0.86 and a beta of 0.54. The business’s 50-day simple moving average is $0.51 and its 200 day simple moving average is $0.70.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01. The company had revenue of $189.56 million during the quarter.

Insider Buying and Selling

In other aTyr Pharma news, Director Paul Schimmel purchased 100,000 shares of aTyr Pharma stock in a transaction that occurred on Wednesday, May 27th. The stock was acquired at an average price of $0.50 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the director owned 779,143 shares of the company’s stock, valued at approximately $389,571.50. This trade represents a 14.72% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 5.75% of the company’s stock.

Institutional Trading of aTyr Pharma

A number of hedge funds have recently made changes to their positions in ATYR. California State Teachers Retirement System bought a new position in shares of aTyr Pharma during the 2nd quarter worth approximately $28,000. Renaissance Technologies LLC bought a new stake in aTyr Pharma in the 1st quarter valued at $32,000. ADAR1 Capital Management LLC lifted its holdings in aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock valued at $40,000 after purchasing an additional 13,385 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new stake in aTyr Pharma during the 4th quarter valued at $41,000. Finally, Legal & General Group Plc acquired a new stake in aTyr Pharma during the 2nd quarter valued at $49,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.